Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Regular screenings, lifestyle modifications and open conversations with healthcare providers can pave the way for healthier ...
HEALTH LITERACY: Understanding osteoporosis: Causes, risk factors, and preventive strategies for bone health ...
The 1.5 million Americans estimated to have the autoimmune disease lupus already have plenty to manage—what with the pain, ...
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback